Breast Cancer 360™ Panel
Helping Your Research
Want a system that provides a unique 360° view of gene expression for the breast tumor, microenvironment, and immune response? If yes, then you have found the right product. The Human nCounter Breast Cancer 360 panel and data analysis report helps researchers quickly decode the complexities of breast cancer biology, develop novel breast cancer gene signatures, and categorize disease heterogeneity using 48 biological signatures including signatures based upon the validated PAM50 and Tumor Inflammation Signature (TIS) assays. Get the most out of your panel by quickly distilling a large amount of data into actionable signatures measuring variables crucial to breast tumor-immune interaction.
How It Works
Highly Curated Content:
Expertly curated, comprehensive content includes 776 genes across 23 key breast cancer pathways and processes, 10 research focused signatures and 30 novel signatures measuring important tumor and immune activities.
Expanded evaluation of breast cancer subtypes including: PAM50 Signature, TNBC, and Claudin-Low Signature.
Interactive, Flexible Report:
The Interactive Breast Cancer 360 data analysis report provides insight into 48 signatures across 13 categories measuring biological variables crucial to breast cancer tumor biology.
You can access validated signatures like PAM50, Tumor Inflammation Signature (TIS), Risk of Recurrence (ROR)/Genomic Risk. Analyze your data by survival, response or grouping variables, or drill down into individual sample variability. Analyze clinical variables by TNBC/PAM50 subtype or variables of your choosing.
Publication Ready Data:
The report generates figures, statistical outputs, methods for your publication, or poster presentation.
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
Includes expertly curated 776 genes across 23 categories of breast cancer tumor biology to support the evaluation of pathways and process, as well as novel signature development.
Content included in the Breast Cancer 360 panel allows for a more comprehensive measurement of biological variables crucial to tumor progression and response to a wide-range of treatments. Research signatures are enriched with potentially predictive genes involved in proliferation, endothelial, angiogenesis, cytotoxicity, stroma, inflammatory chemokines, and apoptosis.
- 48 signatures including two analytically validated signatures- PAM501,2 and Tumor Inflammation Signature3
- 10 research-focused signatures and 30 novel signatures measuring important tumor and immune activities
- adapted to decode breast cancer biology in concert
Analytically Validated Signatures
Included with the Breast Cancer 360 panel is the PAM50 Signature. This 50-gene signature measures a gene expression profile that allows for the classification of breast cancer into four biologically distinct subtypes and a prognostic score.
- PAM50 Subtype
- Luminal A
- Luminal B
- Prosigna Score / Risk of Recurrence
Tumor Inflammation Signature3
Included with the Breast Cancer 360 panel is the Tumor Inflammation Signature. This 18-gene signature measures activity known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade3.
- Includes 4 areas of immune biology used to determine peripherally suppressed immune response and the identification of “hot” or “cold” tumors
- Antigen Presenting Cells
- T Cell/NK presence
- IFNγ Biology
- T Cell Exhaustion
- Tissue-of-origin agnostic (Pan-cancer)
- Potential surrogate for PD-L1 and mutational load in research setting4